Chemically modified tetracycline improves contractility in porcine coronary ischemia/reperfusion injury.
BACKGROUND
Reperfusion of ischemic myocardium has been implicated in extension of infarct size and deleterious clinical outcomes. Anti-inflammatory agents reduce this reperfusion injury. Chemically modified tetracycline-3 (CMT-3) (Collagenex Pharmaceuticals, Newtown, PA, USA) lacks antimicrobial properties yet retains anti-inflammatory activity. We examined infarct size and myocardial function in a porcine coronary artery occlusion/reperfusion model in CMT-3-treated and control animals.


METHODS
Yorkshire pigs (n = 8) underwent median sternotomy, pretreatment with heparin (300 U/kg and 67 U/kg/hr IV) and lidocaine (1 mg/kg IV) and were divided into two groups. Group one (n = 4) had the left anterior descending artery (LAD) occluded for 1 hour, after which it was reperfused for 2 hours. Group two (n = 4) had an identical protocol to group one except CMT-3 (2 mg/kg IV) was administered prior to occlusion of the LAD.


RESULTS
Animals receiving CMT-3 had significantly decreased infarct size in relation to the ventricular area-at-risk (AAR) (28 +/- 9% vs. 64 +/- 8%; p < 0.05). Myocardial contractile function was superior in the CMT-3 treatment, indicated by a higher cardiac index (2.9 +/- 0.3 vs. 2.0 +/- 0.3 L/min/m(2); p < 0.05) and stroke volume index (22 +/- 2 vs. 17 +/- 1 L/m(2)/beat; p < 0.05).


CONCLUSIONS
CMT-3 decreased infarct size in relation to the AAR resulting in relative preservation of contractility, suggesting CMT-3 may improve outcomes during myocardial ischemia reperfusion.
Swartz
Michael F
MF
Department of Surgery, SUNY Upstate Medical University, Syracuse, New York, USA. Swartzm@upstate.edu
Halter
Jeffrey M
JM
Fink
Gregory W
GW
Pavone
Lucio
L
Zaitsev
Alexey
A
Lee
Hsi-Ming
HM
Steinberg
Jay M
JM
Lutz
Charles J
CJ
Sorsa
Timo
T
Gatto
Louis A
LA
Landas
Steve
S
Hare
Christopher
C
Nieman
Gary F
GF